Federal Hemp Law Timeline: What Changes on November 12, 2026
Public Law 119-37 is already enacted. Its revised federal definition of hemp is scheduled to take effect on November 12, 2026—one year after enactment. Until then, the 2018 federal definition remains the baseline for whether cannabis material falls within the federal hemp exception, while FDA rules, state laws, and other requirements continue to apply.
Several bills would repeal, delay, or build a different regulatory framework around the 2026 change. As of July 26, 2026, none has displaced the enacted November 12 effective date. This page tracks the law, the agency work it requires, and the proposals most likely to affect the timetable.
This distinction matters because three different statements are circulating at once:
- Congress enacted a new definition in November 2025.
- The new definition is not yet effective.
- Congress could still amend or repeal it before November 12, 2026.
All three can be true at the same time.
The current federal definition remains in place through November 11
The Agriculture Improvement Act of 2018 defined hemp as Cannabis sativa L. and its parts, derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers with a delta-9 THC concentration no greater than 0.3% on a dry-weight basis.
That definition removed qualifying hemp from the federal Controlled Substances Act definition of marijuana. It did not erase FDA authority, state product rules, or other legal requirements.
Section 781 of Public Law 119-37 says its amendments become effective 365 days after enactment. The law was approved on November 12, 2025, placing the scheduled effective date on November 12, 2026.
An official federal rulemaking document has described the transition this way: products meeting the current 2018 definition remain outside federal controlled-substance treatment as hemp through November 11, 2026, subject to other applicable laws. Beginning November 12, the amended definition controls which products continue to qualify as hemp under the enacted federal text.
What the November 12 definition changes
The new language does more than replace one THC number with another. It changes the measurement named in the plant definition, creates an “industrial hemp” category, defines hemp-derived cannabinoid products, and lists products excluded from “hemp.”
The plant threshold changes to total tetrahydrocannabinols
The amended general definition uses a concentration of no more than 0.3% total tetrahydrocannabinols, including tetrahydrocannabinolic acid, on a dry-weight basis.
That differs from the 2018 language, which names delta-9 THC. The new text expressly includes THCA when describing the total-tetrahydrocannabinols threshold.
Laboratory reports may display delta-9 THC, THCA, and calculated total THC separately. The guide to reading a hemp certificate of analysis explains how to check the analytes, formula, units, dates, and sample identity before drawing a conclusion from those values.
For a product-selection workflow that keeps the current legal timeline separate from product identity and batch evidence, use the THCA Flower Buying Guide.
The law expressly includes “industrial hemp”
The amended text says hemp includes industrial hemp, then defines that term around specified non-cannabinoid stalk and seed uses, certain immature-leaf products, research material that does not enter commerce, and viable seed produced for the listed purposes.
That is one reason “all hemp is banned” is not an accurate description of the enacted text. The law preserves a defined industrial-hemp category while changing how cannabinoid products and other material are treated.
Intermediate cannabinoid products receive their own rules
The law defines an intermediate hemp-derived cannabinoid product as material not yet in its final marketed form, or a powder, liquid, tablet, oil, or other form intended to be mixed, dissolved, formulated, or added to another substance before use.
The exclusions cover intermediate products containing:
- cannabinoids that cannot be naturally produced by Cannabis sativa L.;
- cannabinoids capable of occurring in the plant but synthesized or manufactured outside it; or
- more than 0.3% combined total of total tetrahydrocannabinols, including THCA, and other cannabinoids determined by the Secretary of Health and Human Services to have similar effects or to be marketed as having similar effects.
The law also excludes intermediate products marketed or sold as final products or directly to an end consumer for personal or household use.
Final cannabinoid products receive a per-container threshold
For final hemp-derived cannabinoid products, the enacted exclusion includes products containing more than 0.4 milligrams combined total per container of:
- total tetrahydrocannabinols, including THCA; and
- other naturally produced cannabinoids determined by HHS to have similar effects, or marketed as having similar effects, as tetrahydrocannabinols.
The statute defines “container” as the innermost wrapping, package, or vessel in direct contact with the final product for retail sale, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. It excludes bulk shipping containers and nonessential outer wrapping.
The threshold is expressed per container, not simply as a percentage. Applying it to a specific product requires verified composition, units, package structure, and any relevant agency determinations. A product name or category alone is not enough.
What happens to products excluded from “hemp”
The Controlled Substances Act excludes hemp—using the definition in 7 U.S.C. 1639o—from its definition of marijuana. When the revised definition takes effect, material excluded from “hemp” no longer receives that hemp exception merely because it came from a hemp supply chain.
That does not make every legal question identical. Product composition, drug approvals, statutory exclusions, agency rules, state law, litigation, and enforcement posture can affect the analysis. The careful statement is that products outside the amended hemp definition face federal controlled-substance consequences under the broader legal framework; it is not responsible to decide the status of a particular product without its facts.
Required agency publications: still not located
Section 781 required four agency outputs within 90 days of enactment:
- cannabinoids known to be capable of natural production by Cannabis sativa L.;
- naturally occurring tetrahydrocannabinol-class cannabinoids;
- other known cannabinoids with similar effects, or marketed as having similar effects; and
- added information about the statutory meaning of “container.”
The latest explicit official confirmation we located is the Congressional Research Service report updated May 28, 2026, which said these materials had not yet been published. A fresh search of FDA, HHS, and Federal Register records through July 26 did not locate a later publication. Because an unindexed or differently titled document is possible, this tracker will link the official material as soon as it can be verified.
These materials matter because the amended exclusions depend in part on what can be naturally produced and on federal determinations about similar effects. A private list or a seller’s characterization is not a substitute.
Federal legislation tracker
Introduced bills and filed amendments show what lawmakers want to change. They do not change current law unless the required legislative steps are completed. None of the measures below has changed the November 12, 2026 effective date as of July 26.
| Measure | Latest verified action | What it could change |
|---|---|---|
| H.R. 6209, American Hemp Protection Act | Introduced; referred to an Agriculture subcommittee Jan. 13, 2026 | Repeal section 781 |
| H.R. 7010 | Introduced; referred to an Agriculture subcommittee May 20, 2026 | Replace the 365-day delay with a three-year delay |
| H.R. 7024, Hemp Planting Predictability Act | Introduced; referred to an Agriculture subcommittee May 20, 2026 | Also replace the 365-day delay with a three-year delay |
| S. 3686, Hemp Planting Predictability Act | Introduced; referred to Senate Agriculture Jan. 15, 2026 | Senate proposal for the same three-year change |
| H.R. 7212 | Introduced; referred to House Energy and Commerce Jan. 22, 2026 | Create a federal Food, Drug, and Cosmetic Act pathway for cannabinoid hemp products |
| S. 3474, Cannabinoid Safety and Regulation Act | Introduced; referred to Senate HELP Dec. 15, 2025 | Create another cannabinoid-product regulatory framework |
Two broader House-passed bills also deserve monitoring. H.R. 7567, the Farm, Food, and National Security Act, passed the House April 30 and reached the Senate May 19. H.R. 8646, the FY2027 Agriculture appropriations bill, passed the House June 4 and reached the Senate June 8. The House-passed text of neither bill changes section 781’s November 12 date. Proposed hemp amendments are not enacted text.
If a measure advances, the controlling evidence is its enacted text and effective-date language—not a press release, cosponsor count, filed amendment, or committee discussion.
The April 2026 DEA rule does not change the hemp timetable
A Drug Enforcement Administration final rule effective April 28, 2026 rescheduled FDA-approved marijuana products and state-licensed medical marijuana to Schedule III. The rule expressly says it does not affect hemp as defined in 7 U.S.C. 1639o, and it separately recognizes the November 12, 2026 hemp-definition change.
That rule does not repeal section 781, delay its effective date, or create a federal pathway for ordinary retail THCA products. It should not be presented as a workaround for the enacted hemp amendment.
The December 2025 executive order is direction, not a statutory rewrite
A December 18, 2025 executive order directed federal work on marijuana and CBD research and called for collaboration with Congress on the definition and regulation of final hemp-derived cannabinoid products.
The order is important evidence of executive-branch policy. It did not itself repeal section 781, move the effective date, or enact a new cannabinoid-product pathway. Those changes require the relevant legal process.
FDA law remains a separate layer
Federal hemp status under the Agricultural Marketing Act and Controlled Substances Act is not the same as permission to market a food, dietary supplement, drug, cosmetic, or animal product.
The 2018 Farm Bill preserved FDA authority. FDA’s current public guidance says products containing cannabis-derived compounds remain subject to the Federal Food, Drug, and Cosmetic Act and other laws even when the material meets the federal hemp definition.
FDA has also maintained that CBD and THC products cannot presently be marketed as dietary supplements under its interpretation of the drug-exclusion provisions, and that adding CBD or THC to food introduced into interstate commerce is prohibited under the circumstances described in its guidance. FDA has called for a new regulatory pathway rather than treating hemp status as the end of the inquiry.
State law can be more restrictive or simply different
States regulate cultivation, product definitions, potency, age limits, licensing, testing, packaging, marketing, taxes, and sales channels in different ways. A product’s federal hemp classification does not override a state restriction.
State rules also change on their own schedules. Any availability decision needs a current jurisdiction-specific review, including enacted text, effective dates, regulations, agency guidance, and court orders.
What businesses and readers should watch next
Five developments could materially change this account before November 12:
- Movement on repeal, delay, or regulatory-pathway legislation.
- New FDA or HHS publications required or contemplated by section 781.
- Federal regulations or enforcement guidance addressing implementation.
- Litigation seeking to interpret or block part of the new framework.
- New state laws or rules that take effect before the federal transition.
The date at the top of an article is not enough for a subject moving this quickly. Check the last-reviewed date and the linked official records.
Current bottom line
As verified on July 26, 2026:
- The revised federal hemp definition is enacted and remains scheduled to become effective November 12, 2026.
- The 2018 definition remains the federal baseline through November 11, subject to FDA, state, and other law.
- The enacted change uses total tetrahydrocannabinols, expressly includes THCA, creates industrial-hemp and cannabinoid-product definitions, and imposes new exclusions.
- The latest explicit official confirmation says the required agency lists and container guidance had not been published; no later official publication was located in the July 26 review.
- Pending repeal, delay, and regulatory-framework proposals have not changed current law.
- The April DEA rule and December executive order do not move the section 781 effective date.
- A product’s legal status cannot be determined responsibly from its category name or this article alone.
Related reading
- THCA to Total THC Calculator
- Total THC and THCA: How the Calculation Works—and Where It Does Not
- How to Read a Hemp Bill Without Mistaking It for Law
See Editorial Standards, Sources, and Corrections for IHF's source, date, claims-boundary, and corrections practices.
Primary sources
- Public Law 119-37
- H.R. 6209 actions
- H.R. 7010 actions and text
- H.R. 7212 actions
- H.R. 7024 official status
- S. 3686 official status
- S. 3474 official status
- H.R. 7567 official status
- H.R. 8646 official status
- DEA final rule effective April 28, 2026
- FDA regulation of cannabis and cannabis-derived products
- December 18, 2025 executive order
- Congressional Research Service: Changes to the Statutory Definition of Hemp
Event date: Public Law 119-37 approved November 12, 2025
Scheduled effective date: November 12, 2026
Published: July 12, 2026
Last fact-checked: July 26, 2026
Next review: Weekly through November 20, 2026, and immediately after any relevant federal action.